Teladoc Health - TDOC Stock Forecast, Price & News

29 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last year. There are currently 1 sell rating, 24 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TDOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TDOC, but not buy additional shares or sell existing shares.
View TDOC analyst ratings or view top-rated stocks.

29 brokers have issued twelve-month target prices for Teladoc Health's stock. Their TDOC share price forecasts range from $25.00 to $210.00. On average, they expect the company's stock price to reach $61.03 in the next year. This suggests a possible upside of 133.7% from the stock's current price.
View analysts price targets for TDOC or view top-rated stocks among Wall Street analysts.

Teladoc Health's stock was trading at $91.82 on January 1st, 2022. Since then, TDOC shares have decreased by 71.6% and is now trading at $26.12.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our TDOC earnings forecast.

Teladoc Health, Inc. (NYSE:TDOC) posted its quarterly earnings data on Wednesday, July, 27th. The health services provider reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.27. The health services provider had revenue of $592.38 million for the quarter, compared to the consensus estimate of $586.86 million. Teladoc Health had a negative net margin of 441.94% and a negative trailing twelve-month return on equity of 2.04%.

Teladoc Health issued an update on its third quarter 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of -$0.85--$0.60 for the period, compared to the consensus estimate of -$0.55. The company issued revenue guidance of $600.00 million-$620.00 million, compared to the consensus revenue estimate of $613.73 million.

106 employees have rated Teladoc Health Chief Executive Officer Jason Gorevic on Glassdoor.com. Jason Gorevic has an approval rating of 95% among the company's employees. This puts Jason Gorevic in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Teladoc Health investors own include NVIDIA (NVDA), Tesla (TSLA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Block (SQ), Shopify (SHOP), DocuSign (DOCU), Salesforce (CRM), PayPal (PYPL) and Zoom Video Communications (ZM).

(TDOC) raised $112 million in an IPO on Wednesday, July 1st 2015. The company issued 7,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Teladoc Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."

Shares of TDOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TDOC stock can currently be purchased for approximately $26.12.

Teladoc Health (NYSE:TDOC) has a market capitalization of $4.21 billion and generates $2.03 billion in revenue each year. The health services provider earns $-428,790,000.00 in net income (profit) each year or ($61.40) on an earnings per share basis.

The company employs 5,100 workers across the globe.

Teladoc Health's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The official website for the company is www.teladochealth.com. The health services provider can be reached via phone at (203) 635-2002 or via email at teladoc@westwicke.com.